Disruption of tumor-intrinsic PGAM5 increases anti-PD-1 efficacy through the CCL2 signaling pathway.

IF 10.3 1区 医学 Q1 IMMUNOLOGY
Xiaoying Wei, Hong Wang, Huiquan Liu, Jianguo Wang, Peijie Zhou, Xiaoyang Li, Yuan He, Yan Li, Dong Han, Ting Mei, Yuwen Wang, Ziye Li, Junhao Ning, Zilong Xu, Anlin Wang, Yixuan Li, Jingjing Cheng, Dong Qian
{"title":"Disruption of tumor-intrinsic PGAM5 increases anti-PD-1 efficacy through the CCL2 signaling pathway.","authors":"Xiaoying Wei, Hong Wang, Huiquan Liu, Jianguo Wang, Peijie Zhou, Xiaoyang Li, Yuan He, Yan Li, Dong Han, Ting Mei, Yuwen Wang, Ziye Li, Junhao Ning, Zilong Xu, Anlin Wang, Yixuan Li, Jingjing Cheng, Dong Qian","doi":"10.1136/jitc-2024-009993","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immunosuppressive phenotype compromised immunotherapy efficacy of hepatocellular carcinoma. Tumor cells intrinsic mitochondria dynamics could pass effects on the extracellular microenvironment through mtDNA stress. PGAM5 anchors at mitochondria and regulates mitochondria functions. We aim to explore whether the regulation of tumor-intrinsic PGAM5 on mitochondria affects tumor-infiltrating immune cells in the microenvironment and whether tumor-intrinsic PGAM5 can be a therapeutic target to enhance the immunotherapy efficacy of hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>We analyzed the correlation of PGAM5 expression and immune cells infiltration using Gene Expression Omnibus (GEO) and The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) data sets based on cibersort algorithm and tumor-tissue arrays from two independent cohorts. To further validate our findings, we established subcutaneous and orthotopic mouse HCC models with tumor-intrinsic Pgam5 deficiency and analyzed tumor-infiltrating immune cells by flow cytometry and single-cell RNA sequencing. Mechanistically, we established an in vitro co-culture system and analyzed proteomics data to find out the bridge between tumor cell PGAM5 and tumor-associated macrophages (TAMs) in the microenvironment. Immunofluorescence, chromatin-immunoprecipitation, ELISA, mass spectrometry were conducted to explore the molecular pathway. Macrophages were depleted to investigate whether the effects of tumor-intrinsic PGAM5 on TAMs could affect immunotherapy efficacy in HCC orthotopic and subcutaneous mouse models.</p><p><strong>Results: </strong>PGAM5 expression in tumor was positively correlated with M2-phenotype TAM infiltration in patients with both HCC and mouse HCC tumor models. High tumor-intrinsic PGAM5 expression promoting M2 TAMs infiltration correlated with poor clinical-pathological characteristics and prognosis in patients with HCC. Disruption of tumor-intrinsic Pgam5 reduced TAM M2 polarization and inhibited HCC tumor growth in tumor-bearing mice. Mechanistically, in HCC cells PGAM5 deficiency inhibited mitochondria fission by promoting TRIM28 binding with DRP1, which increased ubiquitination and degradation of DRP1. Tumor-intrinsic PGAM5 deficiency mediated mitochondria fusion and reduced cytosolic mtDNA stress which attenuated TLR9 activation and downstream NF-κB-regulated CCL2 secretion. Furthermore, disruption of tumor-intrinsic Pgam5 significantly facilitated CD8<sup>+</sup> T cells activation and improved anti-programmed cell death protein-1 therapeutic efficacy with macrophages depletion compromising synergistic antitumor immune response.</p><p><strong>Conclusion: </strong>Our results shed light on the effect of tumor mitochondria dynamics on TAMs in tumor microenvironment. Tumor-intrinsic PGAM5 can be a therapeutic target to improve immunotherapy efficacy in patients with HCC.</p>","PeriodicalId":14820,"journal":{"name":"Journal for Immunotherapy of Cancer","volume":"13 1","pages":""},"PeriodicalIF":10.3000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11749670/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal for Immunotherapy of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/jitc-2024-009993","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immunosuppressive phenotype compromised immunotherapy efficacy of hepatocellular carcinoma. Tumor cells intrinsic mitochondria dynamics could pass effects on the extracellular microenvironment through mtDNA stress. PGAM5 anchors at mitochondria and regulates mitochondria functions. We aim to explore whether the regulation of tumor-intrinsic PGAM5 on mitochondria affects tumor-infiltrating immune cells in the microenvironment and whether tumor-intrinsic PGAM5 can be a therapeutic target to enhance the immunotherapy efficacy of hepatocellular carcinoma (HCC).

Methods: We analyzed the correlation of PGAM5 expression and immune cells infiltration using Gene Expression Omnibus (GEO) and The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) data sets based on cibersort algorithm and tumor-tissue arrays from two independent cohorts. To further validate our findings, we established subcutaneous and orthotopic mouse HCC models with tumor-intrinsic Pgam5 deficiency and analyzed tumor-infiltrating immune cells by flow cytometry and single-cell RNA sequencing. Mechanistically, we established an in vitro co-culture system and analyzed proteomics data to find out the bridge between tumor cell PGAM5 and tumor-associated macrophages (TAMs) in the microenvironment. Immunofluorescence, chromatin-immunoprecipitation, ELISA, mass spectrometry were conducted to explore the molecular pathway. Macrophages were depleted to investigate whether the effects of tumor-intrinsic PGAM5 on TAMs could affect immunotherapy efficacy in HCC orthotopic and subcutaneous mouse models.

Results: PGAM5 expression in tumor was positively correlated with M2-phenotype TAM infiltration in patients with both HCC and mouse HCC tumor models. High tumor-intrinsic PGAM5 expression promoting M2 TAMs infiltration correlated with poor clinical-pathological characteristics and prognosis in patients with HCC. Disruption of tumor-intrinsic Pgam5 reduced TAM M2 polarization and inhibited HCC tumor growth in tumor-bearing mice. Mechanistically, in HCC cells PGAM5 deficiency inhibited mitochondria fission by promoting TRIM28 binding with DRP1, which increased ubiquitination and degradation of DRP1. Tumor-intrinsic PGAM5 deficiency mediated mitochondria fusion and reduced cytosolic mtDNA stress which attenuated TLR9 activation and downstream NF-κB-regulated CCL2 secretion. Furthermore, disruption of tumor-intrinsic Pgam5 significantly facilitated CD8+ T cells activation and improved anti-programmed cell death protein-1 therapeutic efficacy with macrophages depletion compromising synergistic antitumor immune response.

Conclusion: Our results shed light on the effect of tumor mitochondria dynamics on TAMs in tumor microenvironment. Tumor-intrinsic PGAM5 can be a therapeutic target to improve immunotherapy efficacy in patients with HCC.

破坏肿瘤固有的PGAM5通过CCL2信号通路增加抗pd -1的功效。
背景:免疫抑制表型影响肝细胞癌的免疫治疗效果。肿瘤细胞内在线粒体动力学可通过mtDNA胁迫对细胞外微环境产生影响。PGAM5锚定在线粒体并调节线粒体功能。我们旨在探讨肿瘤内生性PGAM5对线粒体的调控是否影响微环境中肿瘤浸润性免疫细胞,以及肿瘤内生性PGAM5是否可以作为提高肝细胞癌(HCC)免疫治疗疗效的治疗靶点。方法:利用基因表达图谱(GEO)和肝癌基因组图谱(TCGA-LIHC)数据集,基于网络排序算法和来自两个独立队列的肿瘤组织阵列,分析PGAM5表达与免疫细胞浸润的相关性。为了进一步验证我们的发现,我们建立了肿瘤固有Pgam5缺陷的皮下和原位小鼠HCC模型,并通过流式细胞术和单细胞RNA测序分析了肿瘤浸润免疫细胞。机制上,我们建立体外共培养体系,分析蛋白质组学数据,寻找肿瘤细胞PGAM5与微环境中肿瘤相关巨噬细胞(tumor-associated macrophages, tam)之间的桥梁。采用免疫荧光、染色质-免疫沉淀、ELISA、质谱等方法探讨其分子途径。在肝癌原位和皮下小鼠模型中,我们利用巨噬细胞来研究肿瘤固有的PGAM5对tam的影响是否会影响免疫治疗效果。结果:在肝癌患者和小鼠肝癌肿瘤模型中,PGAM5在肿瘤中的表达与m2表型TAM浸润呈正相关。肿瘤内PGAM5高表达促进M2 tam浸润与HCC患者较差的临床病理特征及预后相关。在荷瘤小鼠中,破坏肿瘤固有的Pgam5可减少TAM M2极化并抑制HCC肿瘤生长。在机制上,在HCC细胞中,PGAM5缺乏通过促进TRIM28与DRP1结合来抑制线粒体裂变,从而增加DRP1的泛素化和降解。肿瘤固有的PGAM5缺陷介导线粒体融合和减少细胞质mtDNA应激,从而减弱TLR9的激活和下游NF-κ b调节的CCL2分泌。此外,破坏肿瘤固有的Pgam5可显著促进CD8+ T细胞活化,提高抗程序性细胞死亡蛋白-1的治疗效果,巨噬细胞耗竭会损害协同抗肿瘤免疫反应。结论:我们的研究结果揭示了肿瘤微环境中线粒体动力学对tam的影响。肿瘤内生性PGAM5可作为提高HCC患者免疫治疗疗效的治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer Biochemistry, Genetics and Molecular Biology-Molecular Medicine
CiteScore
17.70
自引率
4.60%
发文量
522
审稿时长
18 weeks
期刊介绍: The Journal for ImmunoTherapy of Cancer (JITC) is a peer-reviewed publication that promotes scientific exchange and deepens knowledge in the constantly evolving fields of tumor immunology and cancer immunotherapy. With an open access format, JITC encourages widespread access to its findings. The journal covers a wide range of topics, spanning from basic science to translational and clinical research. Key areas of interest include tumor-host interactions, the intricate tumor microenvironment, animal models, the identification of predictive and prognostic immune biomarkers, groundbreaking pharmaceutical and cellular therapies, innovative vaccines, combination immune-based treatments, and the study of immune-related toxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信